CN103565765A - Preparation of ibuprofen orally-disintegrating pellet coated by compound essence powder and capable of hierarchically releasing drug - Google Patents
Preparation of ibuprofen orally-disintegrating pellet coated by compound essence powder and capable of hierarchically releasing drug Download PDFInfo
- Publication number
- CN103565765A CN103565765A CN201210265090.8A CN201210265090A CN103565765A CN 103565765 A CN103565765 A CN 103565765A CN 201210265090 A CN201210265090 A CN 201210265090A CN 103565765 A CN103565765 A CN 103565765A
- Authority
- CN
- China
- Prior art keywords
- powder coating
- ibuprofen
- compound essence
- disintegrating
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to an ibuprofen orally-disintegrating pellet coated by compound essence powder and capable of hierarchically releasing drug. The pellet can cover the spicy taste in the mouth and hierarchically release drug. The preparation method of the ibuprofen orally-disintegrating pellet comprises the following steps: pulverizing ibuprofen micro-particles until the particle size is less than 200 [mu]m; then carrying out three coating processes with three kinds of powder: (1) drug releasing in the mouth: coating part of ibuprofen with compound essence powder so as to obtain orally-disintegrating pellets (I); (2) drug releasing in the stomach: coating part of ibuprofen with gastric soluble powder so as to obtain orally-disintegrating pellets (II); (3) drug releasing in the intestine: coating part of ibuprofen with enteric powder so as to obtain orally-disintegrating pellets (III); evenly mixing the orally-disintegrating pellets (I), (II) and (III) with a vertical press filling agent, a compound disintegrating agent, a flow aid, a lubricant, and a taste modifying agent, and then pressing the mixture into tablets. In the preparation method three orally-disintegrating pellets are prepared, besides the spicy taste of ibuprofen in the mouth is covered, hierarchical releasing of drug in the mouth, stomach, and intestine is achieved, and no prominent grit feeling exists.
Description
One, technical field:
The invention belongs to technical field of medicine.Be specifically related to a kind of release by different level, compound essence powder coating is prepared ibuprofen oral disintegrate piller, then direct compression.
Two, background technology:
Ibuprofen is phenylpropionic acid NSAID (non-steroidal anti-inflammatory drug), has stronger antiinflammatory, analgesia and refrigeration function, and it becomes four large pillar products on China's antipyretic analgesic market together with acetaminophen, aspirin, diclofenac.But ibuprofen has himself advantage in clinical practice.Be all febrifuge safely and effectively, at body temperature, during higher than 39.2 ℃, ibuprofen is than more effective with the acetaminophen of dosage, and the time of bringing down a fever is long.Pharmacodynamic study proves, the analgesia of ibuprofen, refrigeration function are respectively aspirin and 28 times and 20 times, its untoward reaction is fewer and light than aspirin, clinical practice through more than 30 years, ibuprofen has withstood time and the masses' test, is used as the drug of first choice of current clinical anti-inflammatory joint disease.
The research of current domestic ibuprofen dosage form mainly contains tablet, granule, oral solution, oral slow-releasing preparation, injection, preparation capable of permeating skin, rectal suppository, solid dispersion etc., conventional dosage forms is large to GI irritation, bioavailability is low, feels sick, the side effect such as vomiting, erythra is larger.And the feature of novel ibuprofen oral disintegrating tablets is:
1 absorbs soon, and bioavailability is high.Oral cavity disintegration tablet can affect the rate of dissolution of medicine, and the particularly impact on insoluble medicine rate of dissolution, therefore make the bioavailability that oral cavity disintegration tablet can improve medicine.Oral cavity disintegration tablet is applicable to onset rapidly, and valid density and poisoning concentration differ larger medicine, and some war wound emergency treatment medicines, NSAID (non-steroidal anti-inflammatory drug), spasmolytic Bendectin and analgesic etc. all are relatively applicable to making oral cavity disintegration tablet; Other medicine, if blood drug level is for a long time in compared with plateau, easily produces drug resistance, makes after oral cavity disintegration tablet, can overcome this problem, produces good therapeutic effect.
2 taking conveniences.Oral cavity disintegration tablet needn't be used water delivery service, saliva can make its disintegrate or dissolving, both can swallow by conventional tablet, can be placed in water and take after disintegrate again, also can not need to take medicine with water swallow, be particularly useful for the patient of old man, children's, dysphagia and the inconvenient person that fetches water takes medicine convenience is provided, if adopt in the preparation certain method to improve the mouthfeel of preparation, can greatly improve the drug compliance of child patient, solve the problem of taking baby ' difficulty.
3 intestinals are residual few, and side effect is low.As instant in the piroxicam gastrointestinal reaction rate than diclofenac and naproxen ordinary tablet is low.Antipyretic analgesic aspirin, the rapid disintegrate of ibuprofen speed disintegrating tablet energy before medicine arrives gastrointestinal tract are also dispersed into trickle granule, cause medicine to distribute in gastrointestinal tract large area, and absorption point increases, thereby has reduced medicine to gastrointestinal local excitation.
4 avoid the first pass effect of liver.Due to oral cavity disintegration tablet disintegrate rapidly in mouth, except major part enters gastrointestinal tract with swallowing act, also there is considerable part direct oral cavity to absorb, thereby rapid-action, first pass effect is little.
5 local therapeutic effects.It is emptying rapidly that common oral solid formulation (tablet, capsule) arrives stomach bottom, is difficult to reach the Targeting Effect of stomach.The oral cavity disintegration tablet of anion exchange resin-containing, because it is at dissolved in oral cavity, resin is evenly distributed at gastric, and 10% medicine, Entogastric lingering 5.5 hours, can carry out topical therapeutic to helicobacter pylori.
Along with the development of spray drying technology, solid solution technology and direct compression of full-powder technology, and the exploitation of good adjuvant, oral cavity disintegration tablet develops by its unique feature rapidly, has good market prospect.
Ibuprofen crude drug itself has particularity, and its acid can produce strong impulse to throat, so the mouthfeel of ibuprofen oral disintegrating tablets is the difficult point of formulation and technology.In order to cover the acid of crude drug, the method conventionally adopting has the correctives of adding.Correctives generally comprises sweeting agent, aromatic, mucilage and effervescent four classes.Sweeting agent can be covered salty, the puckery and bitterness of medicine; Aromatic in medicament in order to improve spice and the essence of the abnormal smells from the patient of medicament; Mucilage has the character that thickness relaxes, and can disturb the sense of taste of taste bud and has the effect of taste masking; Effervescent system utilizes organic acid (as citric acid, tartaric acid) to mix with sodium bicarbonate, after chance water, produces great amount of carbon dioxide, is acid because carbon dioxide is water-soluble, can benumb taste bud and taste masking.By adding correctives, promote taste bud to sweet, sour, cool, hot, sliding impression and the impression of nervi olfactory to fragrance, obscure the brain sense of taste, cover the taste of medicine itself, therefore add correctives taste masking, it is the method that preparation override is considered, medicine to the micro-hardship of low dose of mouthfeel is effective, but to the heavy dose of and strong medicine of bitterness, must on the basis of correctives, adopt taste masking technology targetedly adding.Conventional taste masking technology has the technology such as granulation, lipid microsphere, regulation and control pH, resin complexes, coating, reduces medicine and in saliva, dissolves and discharge, and reduces the combination of drug molecule and taste bud, reaches the object of taste masking.
CN101978955A discloses a kind of Dextral ibuprofen amino acid salt tablets and preparation method thereof, adopt wet method, dry granulation tabletting, direct powder compression, also can carry out coating to tablet, can be prepared into ordinary tablet, chewable tablet, effervescent tablet, oral instant-dissolving tablet, coated tablet and Film coated tablets, main component is Dexibuprofen amino acid salt, and onset is rapid, few side effects.
CN102488681A discloses a kind of ibuprofen diphenhydramine oral cavity disintegration tablet and preparation method thereof, and it is ibuprofen 40%, diphhydramine hydrochloride 5% or diphenhydramine citrate 7.6%, filler 35%-40%, disintegrating agent 6%-12%, gas-producing disintegrant 0-5%, binding agent 1%-2%, surfactant 1%-2.5%, lubricant 1%-1.5%, sweeting agent 0.7%-2,5% and aromatic 0-0.5% that prescription forms; Prepared oral cavity disintegration tablet meets the prescription of oral cavity disintegration tablet, appearance looks elegant, and mouthfeel is good, steady quality.
CN101455653A discloses a kind of arginine ibuprofen oral disintegrating tablets, active component arginine Ibuprofen and suitable pharmaceutic adjuvant, consists of.Its percentage by weight is arginine Ibuprofen 20%-60%, adjuvant 40%-80%.Adjuvant comprises: the mixture of one or more in diluent (filler), disintegrating agent, binding agent, wetting agent, lubricant, correctives, coloring agent, gas-producing disintegrant.Adopt correctives, mucilage, packaging technique or the above-mentioned several different methods of integrated use to cover the acid of principal agent.
Powder coating technology is a kind of novel packaging technique, cover the bad taste of smelling of medicine, improve the stability and the compatibility stability of improving medicine of preparation, in coating material, add compound essence can reach the object of dual taste masking, the use of compound essence has simultaneously brought unique armaticity to oral cavity disintegration tablet, increase the compliance of patient's medication, be more applicable to old man and child's medication.The present invention wishes to prepare a kind of ibuprofen oral disintegrating tablets, do not need ibuprofen to carry out precursor modification, but the simple compound essence powder coating of adopting process technology is prepared Orally disintegrating piller, reaches the object of covering ibuprofen acid.Wherein adopt different coating materials to carry out powder coating, can obtain the Orally-disintegrating tablet piller of different release approach, make ibuprofen present with different levels drug release behavior.
Three, summary of the invention:
The object of the invention is: a kind of taking convenience is provided, and mouthfeel is good, there is unique armaticity, and the Orally disintegrating piller of release by different level and preparation method thereof.
Object of the present invention can be achieved through the following technical solutions.
The compound essence powder coating of the present invention preparation method that the ibuprofen mouth of release collapses piller is by different level: first ibuprofen is carried out to micronization, then recipe quantity ibuprofen is carried out to three kinds of multi-form powder coatings, obtain three kinds of Orally disintegrating pillers, tabletting after three kinds of Orally disintegrating pillers are mixed homogeneously with vertical compression filler, compound disintegrating agent, fluidizer, lubricant and correctives.
Ibuprofen is carried out to micronization, and object is to promote its dissolving and stripping, controls its particle diameter and is less than 200 μ m.Take recipe quantity micronization principal agent, adopt following steps to carry out the powder coating of principal agent:
(1) compound essence powder coating, obtains Orally disintegrating piller (I), mainly release in oral cavity;
(2) gastric solubility coating material powder coating, obtains Orally disintegrating piller (II), mainly release under one's belt;
(3) enteric-coating material powder coating, obtains Orally disintegrating piller (III), mainly release in intestinal.
Compound essence powder coating technology is that compound essence is scattered in to absorption, dissolves or is melted in coating material, adopts fluid bed or fusion method to carry out powder coating.The micronized ibuprofen of first is carried out to powder coating.Compound essence be selected from orange flavor, Fructus Citri Limoniae essence, Fructus Citri tangerinae essence, Mint Essence, kiwi fruit essence, spice, Herba Menthae Rotundifoliae two kinds or more than; Coating material is selected from one or more in acrylic resin, ethylene copolymer, cyclodextrin and derivant thereof, Rikemal B 200, ethylene copolymer, gelatin; The ratio of compound essence rain coating material is 1: 10～3: 7, preferably 1: 7～1: 3; Compound essence powder coating makes principal agent weightening finish for 2-20%, and preferably principal agent weightening finish is 5-15%, more preferably 6%-12%; The order number of the Orally disintegrating piller (I) that compound essence powder coating is prepared is 20～60 orders, preferably 35～50 orders.
In gastric solubility coating material powder coating, coating material is selected from one or more in cellulose derivative, polyvidone, crylic acid resin, AEA; Gastric solubility coating material powder coating makes principal agent weightening finish for 40-150%, and preferably principal agent weightening finish is 60-130%, more preferably 80%-110%; The order number of the Orally disintegrating piller (II) that gastric solubility coating material powder coating is prepared is 20～50 orders, preferably 30～45 orders.。
Enteric coatings material is selected from one or more in Lac, CAP, acrylic resin, hydroxypropyl methyl cellulose phthalate, hydroxypropyl methylcellulose acetate succinate; Powder coating makes principal agent weightening finish for 30-150%, and preferably principal agent weightening finish is 65-135%, more preferably 85%-120%; The order number of the Orally disintegrating piller (III) that enteric coatings material powder coating is prepared is 20～50 orders, preferably 30～45 orders.。
Compound disintegrating agent described in the present invention is selected from one or more of hypromellose, cross-linking sodium carboxymethyl cellulose, crospovidone and carboxymethyl starch sodium of low replacement, combines use gas-producing disintegrant simultaneously; Gas-producing disintegrant is selected from one or more of sodium bicarbonate and citric acid, sodium bicarbonate and tartaric acid, sodium bicarbonate and citric acid and sodium bicarbonate and fumaric acid.Wherein gas-producing disintegrant not only has the effect that promotes disintegrate, and gas-producing disintegrant is also a kind of correctives simultaneously, adds gas-producing disintegrant also to have the ibuprofen of covering acid and irritating effect in oral cavity disintegration tablet.
The filler of vertical compression described in the present invention is microcrystalline Cellulose, spray one or more in dry lactose, Lactis Anhydrous, pre-paying starch; Fluidizer and lubricant are one or more in micropowder silica gel, aerosil, magnesium stearate, calcium hydrogen phosphate, Polyethylene Glycol; Correctives is one or more in aspartame, sorbitol, mannitol.
Ibuprofen has been carried out to three kinds of multi-form powder coatings, prepared 3 kinds of Orally disintegrating pillers, respectively release in oral cavity, harmonization of the stomach intestinal.On the one hand because the ibuprofen discharging in oral cavity reduces, ibuprofen is reduced the zest of the oral mucosa of throat, because the ibuprofen discharging in oral cavity is through compound essence powder coating, unique armaticity of compound essence and powder coating technology can dually be covered the acid of ibuprofen simultaneously; Different Orally disintegrating pillers, makes ibuprofen present release by different level on the other hand, has reduced the mucosa irritation of ibuprofen to each position.
Four, the specific embodiment:
Embodiment 1
Preparation method: ibuprofen is carried out to comminution by gas stream micronization, control its particle diameter and be less than 200 μ m.Micronization ibuprofen is divided into three parts, carries out respectively powder coating, step is as follows:
(1) compound essence powder coating, 20g micronization ibuprofen is placed in to fluid bed, orange flavor and Fructus Citri Limoniae essence are dispersed in Eudragit E 100 coating materials (ratio of compound essence and coating material is 1: 3), make principal agent weightening finish 10%, obtain 35～50 object Orally disintegrating pillers (I);
(2) gastric solubility coating material powder coating, is placed in fluid bed by 15g micronization ibuprofen, and the acrylic resin of take is coating material No. IV, makes principal agent weightening finish 90%, obtains 30～45 object Orally disintegrating pillers (II);
(3) enteric-coating material powder coating, is placed in fluid bed by 15g micronization ibuprofen, and the acrylic resin of take is coating material No. II, makes principal agent weightening finish 100%, obtains 30～45 object Orally disintegrating pillers (III).
Direct compression after medicine after powder coating is mixed homogeneously with recipe quantity Lactis Anhydrous, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, citric acid, sodium bicarbonate, aspartame, magnesium stearate and micropowder silica gel.
Embodiment 2
Preparation method: ibuprofen is carried out to ball mill pulverizing micronization, control its particle diameter and be less than 200 μ m.Micronization ibuprofen is divided into three parts, carries out respectively powder coating, step is as follows:
(1) compound essence powder coating, 20g micronization ibuprofen is placed in to fluid bed, orange flavor and Fructus Citri tangerinae essence are dispersed in Eudragit E 100 and acrylic resin NE30D mixing coating material (ratio of compound essence and coating material is 1: 4), make principal agent weightening finish 10%, obtain 35～50 object Orally disintegrating pillers (I);
(2) gastric solubility coating material powder coating, is placed in fluid bed by 15g micronization ibuprofen, and the acrylic resin of take is coating material No. IV, makes principal agent weightening finish 90%, obtains 30～45 object Orally disintegrating pillers (II);
(3) enteric-coating material powder coating, is placed in fluid bed by 15g micronization ibuprofen, and the acrylic resin of take is coating material No. II, makes principal agent weightening finish 100%, obtains 30～45 object Orally disintegrating pillers (III).
Direct compression after medicine after powder coating is mixed homogeneously with recipe quantity Lactis Anhydrous, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, citric acid, sodium bicarbonate, aspartame, magnesium stearate and micropowder silica gel.
Embodiment 3
Preparation method: ibuprofen is carried out to ball mill pulverizing micronization, control its particle diameter and be less than 200 μ m.Micronization ibuprofen is divided into three parts, carries out respectively powder coating, step is as follows:
(1) compound essence powder coating, 20g micronization ibuprofen is placed in to fluid bed, orange flavor and Fructus Citri tangerinae essence are dispersed in Eudragit E 100 coating materials (ratio of compound essence and coating material is 1: 7), make principal agent weightening finish 8%, obtain 35～50 object Orally disintegrating pillers (I);
(2) gastric solubility coating material powder coating, is placed in fluid bed by 15g micronization ibuprofen, and the acrylic resin of take is coating material No. IV, makes principal agent weightening finish 100%, obtains 30～45 object Orally disintegrating pillers (II);
(3) enteric-coating material powder coating, is placed in fluid bed by 15g micronization ibuprofen, and the acrylic resin of take is coating material No. II, makes principal agent weightening finish 120%, obtains 30～45 object Orally disintegrating pillers (III).
Direct compression after medicine after powder coating is mixed homogeneously with recipe quantity Lactis Anhydrous, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, citric acid, sodium bicarbonate, aspartame, magnesium stearate and micropowder silica gel.
Embodiment 4
Preparation method: ibuprofen is carried out to comminution by gas stream micronization, control its particle diameter and be less than 200 μ m.Micronization ibuprofen is divided into three parts, carries out respectively powder coating, step is as follows:
(1) compound essence powder coating, 20g micronization ibuprofen is placed in to fluid bed, kiwi fruit essence and Fructus Citri tangerinae essence are dispersed in Eudragit E 100 and acrylic resin NE30D mixing coating material (ratio of compound essence and coating material is 1: 4), make principal agent weightening finish 10%, obtain 35～50 object Orally disintegrating pillers (I);
(2) gastric solubility coating material powder coating, is placed in fluid bed by 15g micronization ibuprofen, and the acrylic resin of take is coating material No. IV, makes principal agent weightening finish 100%, obtains 30～45 object Orally disintegrating pillers (II);
(3) enteric-coating material powder coating, is placed in fluid bed by 15g micronization ibuprofen, and the acrylic resin of take is coating material No. II, makes principal agent weightening finish 100%, obtains 30～45 object Orally disintegrating pillers (III).
Direct compression after medicine after powder coating is mixed homogeneously with recipe quantity Lactis Anhydrous, microcrystalline Cellulose, mannitol, cross-linking sodium carboxymethyl cellulose, citric acid, sodium bicarbonate, aspartame, magnesium stearate and micropowder silica gel.
Embodiment 5
Preparation method: ibuprofen is carried out to comminution by gas stream micronization, control its particle diameter and be less than 200 μ m.Micronization ibuprofen is divided into three parts, carries out respectively powder coating, step is as follows:
(1) compound essence powder coating, 20g micronization ibuprofen is placed in to fluid bed, kiwi fruit essence and Fructus Citri tangerinae essence are dispersed in Eudragit E 100 coating materials (ratio of compound essence and coating material is 1: 3), make principal agent weightening finish 10%, obtain 35～50 object Orally disintegrating pillers (I);
(2) gastric solubility coating material powder coating, is placed in fluid bed by 15g micronization ibuprofen, and the acrylic resin of take is coating material No. IV, makes principal agent weightening finish 100%, obtains 30～45 object Orally disintegrating pillers (II);
(3) enteric-coating material powder coating, is placed in fluid bed by 15g micronization ibuprofen, and hydroxypropyl methyl cellulose phthalate is coating material, makes principal agent weightening finish 110%, obtains 30～45 object Orally disintegrating pillers (III).
Direct compression after medicine after powder coating is mixed homogeneously with recipe quantity Lactis Anhydrous, microcrystalline Cellulose, mannitol, carboxymethyl starch sodium, citric acid, sodium bicarbonate, aspartame, magnesium stearate and micropowder silica gel.
Claims (19)
1. the compound essence powder coating preparation that the ibuprofen mouth of release collapses piller by different level, it is characterized in that ibuprofen micronization, ibuprofen is carried out to three kinds of multi-form powder coatings, obtain three kinds of Orally disintegrating pillers, tabletting after three kinds of Orally disintegrating pillers are mixed homogeneously with vertical compression filler, compound disintegrating agent, fluidizer, lubricant and correctives.
2. the compound essence powder coating according to claim 1 preparation that the ibuprofen mouth of release collapses piller by different level, is characterized in that the micronized particle diameter of ibuprofen is less than 200 μ m.
3. the compound essence powder coating according to claim 1 preparation that the ibuprofen mouth of release collapses piller by different level, it is characterized in that three kinds of described multi-form powder coating methods are, take recipe quantity micronization principal agent, adopt following steps to carry out the powder coating of principal agent:
(1) compound essence powder coating, obtains Orally disintegrating piller (I), mainly release in oral cavity;
(2) gastric solubility coating material powder coating, obtains Orally disintegrating piller (II), mainly release under one's belt;
(3) enteric-coating material powder coating, obtains Orally disintegrating piller (III), mainly release in intestinal.
4. powder coating according to claim 3, what it is characterized in that powder coating adopts is fluid bed or fusion method powder coating.
5. compound essence powder coating according to claim 3, is characterized in that compound essence is scattered in to absorption, dissolves or is melted in coating material carries out powder coating
6. compound essence powder coating according to claim 3, is characterized in that coating material is one or more in acrylic resin, ethylene copolymer, cyclodextrin and derivant thereof, Rikemal B 200, ethylene copolymer, gelatin.、
7. compound essence powder coating according to claim 3, it is characterized in that described compound essence be selected from orange flavor, Fructus Citri Limoniae essence, Fructus Citri tangerinae essence, Mint Essence, kiwi fruit essence, spice, Herba Menthae Rotundifoliae two kinds or more than.
8. compound essence powder coating according to claim 3, is characterized in that described compound essence and the ratio of minute coating material are 1: 10～3: 7, preferably 1: 7～1: 3.
9. compound essence powder coating according to claim 3, is characterized in that compound essence powder coating makes principal agent weightening finish for 2-20%.
10. compound essence powder coating according to claim 9, is characterized in that principal agent weightening finish is for 5-15%, preferably 6%-12%.
11. compound essence powder coatings according to claim 3, is characterized in that the order number of the Orally disintegrating piller (I) that compound essence powder coating is prepared is 20～60 orders, preferably 35～50 orders.
12. gastric solubility coating material powder coatings according to claim 3, is characterized in that described gastric solubility coating material is selected from one or more in cellulose derivative, polyvidone, crylic acid resin, AEA.
13. gastric solubility coating material powder coatings according to claim 12, is characterized in that described powder coating makes principal agent weightening finish for 40-150%, and preferably principal agent weightening finish is 60-130%, more preferably 80%-110%.
14. gastric solubility coating material powder coatings according to claim 3, is characterized in that the order number of the Orally disintegrating piller (II) that gastric solubility coating material powder coating is prepared is 20～50 orders, preferably 30～45 orders.
15. enteric-coating material powder coatings according to claim 3, is characterized in that described enteric coatings material is selected from one or more in Lac, CAP, acrylic resin, hydroxypropyl methyl cellulose phthalate, hydroxypropyl methylcellulose acetate succinate.
16. enteric coatings material powder coatings according to claim 15, is characterized in that described powder coating makes principal agent weightening finish for 30-150%, and preferably principal agent weightening finish is 65-135%, more preferably 85%-120%.
17. enteric coatings material powder coatings according to claim 3, is characterized in that the order number of the Orally disintegrating piller (III) that enteric coatings material powder coating is prepared is 20～50 orders, preferably 30～45 orders.
The 18. compound essence powder coating according to claim 1 preparations that the ibuprofen mouth of release collapses piller by different level, it is characterized in that described compound disintegrating agent is selected from one or more of hypromellose, cross-linking sodium carboxymethyl cellulose, crospovidone and carboxymethyl starch sodium of low replacement, combine use gas-producing disintegrant, gas-producing disintegrant is selected from one or more in sodium bicarbonate and citric acid, sodium bicarbonate and tartaric acid, sodium bicarbonate and citric acid and sodium bicarbonate and fumaric acid simultaneously.
The 19. compound essence powder coating according to claim 1 preparations that the ibuprofen mouth of release collapses piller by different level, is characterized in that described vertical compression filler is microcrystalline Cellulose, sprays one or more in dry lactose, Lactis Anhydrous, pre-paying starch; Fluidizer and lubricant are one or more in micropowder silica gel, aerosil, magnesium stearate, calcium hydrogen phosphate, Polyethylene Glycol; Correctives is one or more in aspartame, sorbitol, mannitol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210265090.8A CN103565765B (en) | 2012-07-30 | 2012-07-30 | The ibuprofen mouth of compound essence powder coating release by different level collapses the preparation of piller |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210265090.8A CN103565765B (en) | 2012-07-30 | 2012-07-30 | The ibuprofen mouth of compound essence powder coating release by different level collapses the preparation of piller |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103565765A true CN103565765A (en) | 2014-02-12 |
| CN103565765B CN103565765B (en) | 2015-08-26 |
Family
ID=50039048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210265090.8A Expired - Fee Related CN103565765B (en) | 2012-07-30 | 2012-07-30 | The ibuprofen mouth of compound essence powder coating release by different level collapses the preparation of piller |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103565765B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103536538A (en) * | 2013-10-23 | 2014-01-29 | 海南康芝药业股份有限公司 | Expansive pellet for effectively masking taste and preparation method thereof |
| CN106983734A (en) * | 2017-06-01 | 2017-07-28 | 海南妙音春制药有限公司 | A kind of ibuprofen sustained release capsules and preparation method thereof |
| CN107184565A (en) * | 2017-06-01 | 2017-09-22 | 海南妙音春制药有限公司 | A kind of preparation method of ibuprofen sustained release capsules |
| CN110917165A (en) * | 2019-12-26 | 2020-03-27 | 北京鑫开元医药科技有限公司海南分公司 | Ibuprofen orally disintegrating tablet and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101548953A (en) * | 2008-04-03 | 2009-10-07 | 上海医药工业研究院 | Medicine granule, preparation method thereof, and preparation containing same |
| CN102327244A (en) * | 2011-09-30 | 2012-01-25 | 杭州康恩贝制药有限公司 | Ambroxol hydrochloride orally disintegrating tablet and preparation method thereof |
-
2012
- 2012-07-30 CN CN201210265090.8A patent/CN103565765B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101548953A (en) * | 2008-04-03 | 2009-10-07 | 上海医药工业研究院 | Medicine granule, preparation method thereof, and preparation containing same |
| CN102327244A (en) * | 2011-09-30 | 2012-01-25 | 杭州康恩贝制药有限公司 | Ambroxol hydrochloride orally disintegrating tablet and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 张玥等: "对于口服药物掩味方法的研究进展", 《中国实用医药》, vol. 3, no. 13, 31 May 2008 (2008-05-31), pages 195 - 196 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103536538A (en) * | 2013-10-23 | 2014-01-29 | 海南康芝药业股份有限公司 | Expansive pellet for effectively masking taste and preparation method thereof |
| CN106983734A (en) * | 2017-06-01 | 2017-07-28 | 海南妙音春制药有限公司 | A kind of ibuprofen sustained release capsules and preparation method thereof |
| CN107184565A (en) * | 2017-06-01 | 2017-09-22 | 海南妙音春制药有限公司 | A kind of preparation method of ibuprofen sustained release capsules |
| CN107184565B (en) * | 2017-06-01 | 2018-04-03 | 海南妙音春制药有限公司 | A kind of preparation method of ibuprofen sustained release capsules |
| CN106983734B (en) * | 2017-06-01 | 2018-09-14 | 海南妙音春制药有限公司 | A kind of ibuprofen sustained release capsules and preparation method thereof |
| CN110917165A (en) * | 2019-12-26 | 2020-03-27 | 北京鑫开元医药科技有限公司海南分公司 | Ibuprofen orally disintegrating tablet and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103565765B (en) | 2015-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5535616B2 (en) | Direct compressible composite for orally disintegrating tablets | |
| AU2010283609B2 (en) | Novel pharmaceutical formulations against drug misuse | |
| US20090311321A1 (en) | Oral disintegrating tablet having masked bitter taste and method for production thereof | |
| JP2009114113A (en) | Intraorally disintegrable tablet and method for producing the same | |
| JP2005527508A (en) | Rapid melting multiparticulate formulation for oral delivery | |
| JP2023063386A (en) | Orally administered formulation masking bitterness of silodosin | |
| CN103402497A (en) | Rapidly dispersing granules, orally disintegrating tablets and methods | |
| CN102526058A (en) | Anti-inflammatory analgesic medicinal composition containing lornoxicam and esomeprazole | |
| BRPI0812064B1 (en) | pharmaceutical formulation in the form of agglomerates, tablets, and process for producing a pharmaceutical formulation | |
| US11135188B2 (en) | Method and composition to improve absorption of therapeutic agents | |
| JP6919119B2 (en) | A compressed solid pharmaceutical composition containing a γ-aminobutyric acid derivative substituted at the 3-position. | |
| WO2007011018A1 (en) | Rapidly disintegratable oral tablet | |
| CN103565765B (en) | The ibuprofen mouth of compound essence powder coating release by different level collapses the preparation of piller | |
| JP2007517011A (en) | Multiparticulate formulation for oral delivery | |
| A AlHusban et al. | Recent patents and trends in orally disintegrating tablets | |
| JP2019163335A (en) | Effervescent composition and method of making it | |
| US20130122098A1 (en) | Method and composition to improve absorption of therapeutic agents | |
| CN106822907B (en) | Two-phase release preparation containing racecadotril and preparation method thereof | |
| CN102125540A (en) | Pharmaceutically acceptable composition containing ambroxol in non-salt form | |
| CN101700245B (en) | Compound drug for curing colds and preparation technology thereof | |
| CN101411702B (en) | Nefopam hydrochloride naproxen sodium compound sustained-release preparation and preparation method thereof | |
| JP2008081448A (en) | Bitterness masking rapid release particle of zolpidem tartrate | |
| CN100448431C (en) | Oral disintegrated Anfenmame tablet for treating children's cold and its prepn | |
| JP4052603B2 (en) | Formulation for oral administration | |
| WO2005011637A1 (en) | At-use dispersed preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150826 Termination date: 20160730 |